1 |
NCT02736916 |
Recruiting |
HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell Lung
|
- Radiation: HS-WBRT PCI
- Radiation: Conventional PCI
|
Interventional |
Not Applicable |
- General Hospital of Ningxia Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Evaluate delayed recall as assessed by the Hopkins Verbal Learning Test-Revised (HVTL-R) 4 months after hippocampal sparing during whole-brain radiotherapy (HS-WBRT) for PCI of limited stage small cell lung cancer patients.
- Evaluate the rate of brain metastasis in hippocampal region after HS-WBRT PCI for limited stage small cell lung cancer patients.
|
3 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02736916 |
Radiation Oncology 20160101 |
|
March 2016 |
March 2018 |
December 2018 |
April 13, 2016 |
April 13, 2016 |
|
- General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
|
2 |
NCT02688036 |
Recruiting |
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC |
- Carcinoma, Small Cell
- Lung Neoplasms
|
- Radiation: hypofractionated concurrent chemoradiotherapy
- Radiation: conventionally fractionated concurrent chemoradiotherapy
|
Interventional |
Phase 3 |
- Chinese Academy of Medical Sciences
- Sun Yat-sen University
- Fudan University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- disease free survival
- local-regional failure (Incidence of tumor recurrence in local or regional area)
- toxicity (Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0)
|
860 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02688036 |
CH-L-045/2 |
|
February 2016 |
December 2019 |
May 2020 |
February 23, 2016 |
January 2, 2018 |
|
- Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences
Beijing, China
|
3 |
NCT02675088 |
Not yet recruiting |
Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer |
- Carcinoma, Small Cell
- Lung Neoplasms
|
- Radiation: high-dose TRT
- Radiation: standard-dose TRT
|
Interventional |
Phase 3 |
- Chinese Academy of Medical Sciences
- Sun Yat-sen University
- Fudan University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival
- progression-free survival
- Incidence of tumor recurrence in local or regional area
- Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0
|
186 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02675088 |
CH-L-045/1 |
|
March 2016 |
December 2017 |
December 2019 |
February 5, 2016 |
February 8, 2016 |
|
|
4 |
NCT02146170 |
Recruiting |
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors |
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Extrapulmonary Small Cell Cancer
- (and 2 more...)
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.
- Follow the natural history of patients with thoracic malignancies.
- Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic ...
|
2000 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02146170 |
140105 14-C-0105 |
|
May 8, 2014 |
April 30, 2024 |
April 30, 2025 |
May 23, 2014 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
5 |
NCT00263731 |
Recruiting |
Metabolomic Analysis of Lung Cancer |
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Small Cell Lung
|
|
Observational |
|
- James Graham Brown Cancer Center
- University of Louisville
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- metabolic profiles of cancerous vs. healthy lung tissue
- glycolytic metabolism in plasma
- metabolic markers in urine
- (and 3 more...)
|
750 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00263731 |
523.05 BCC-LUN-05-002 |
|
December 2005 |
December 2018 |
December 2018 |
December 9, 2005 |
November 23, 2016 |
|
- James Graham Brown Cancer Center, University of Louisville
Louisville, Kentucky, United States
|
6 |
NCT02487095 |
Recruiting |
Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers Amd Extrapulmonary Small Cell Cancers |
- Carcinoma, Non-Small -Cell Lung
- Ovarian Neoplasms
- Small Cell Lung Carcinoma
- (and 3 more...)
|
- Drug: Topotecan
- Drug: VX-970
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ph I: Maximum Tolerated Dose (MTD) of topotecan in combination with VX-970
- Ph II: Clinical Response Rate
|
70 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02487095 |
150150 15-C-0150 |
|
June 18, 2015 |
May 31, 2024 |
October 30, 2025 |
July 1, 2015 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
7 |
NCT01306045 |
Recruiting |
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
- Carcinoma, Thymic
|
- Drug: AZD6244
- Drug: MK-2206
- Drug: Lapatinib
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility of the use of tumor molecular profiling and targeted therapies in the treatment of NSCLC, SCLC, and Thymic Malignancies
- To estimate the response rate of molecular-profile directed treatments in NSCLC, SCLC, and Thymic Malignancies
|
600 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01306045 |
110096 11-C-0096 |
|
February 26, 2011 |
January 31, 2019 |
December 30, 2019 |
March 1, 2011 |
February 8, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
8 |
NCT01970696 |
Recruiting |
International Ovarian & Testicular Stromal Tumor Registry |
- Ovarian Stromal Tumor
- Testicular Stromal Tumors
- Ovarian Small Cell Carcinoma
- DICER1 Syndrome
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Dana-Farber Cancer Institute
- (and 10 more...)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Other
|
- DICER1 mutations in ovarian and testicular stromal tumors
- Clinical factors associated with outcome in ovarian and testicular stromal tumors
- Pathologic and Genetic Correlations
|
200 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT01970696 |
International OTST Registry |
OTST |
December 2011 |
December 2020 |
|
October 28, 2013 |
November 6, 2017 |
|
- Children's Minnesota
Minneapolis, Minnesota, United States
|
9 |
NCT02995187 |
Recruiting |
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) |
|
- Drug: Apatinib Mesylate tablet
|
Interventional |
Phase 2 |
- Chinese Academy of Medical Sciences
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Disease Control Rate
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
25 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02995187 |
CH-L-061 |
|
December 2016 |
May 2018 |
September 2018 |
December 16, 2016 |
September 7, 2017 |
|
- Chinese Academy of Medical Sciences
Beijing, China
|
10 |
NCT02893917 |
Recruiting |
Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer |
- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- (and 5 more...)
|
- Drug: Cediranib
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Radiographic progression free survival
- Overall survival
- Objective response rate assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- (and 4 more...)
|
90 |
Male |
18 Years and older (Adult, Senior) |
NCT02893917 |
NCI-2016-01346 2000020461 9984 UM1CA186689 |
|
December 23, 2016 |
June 30, 2018 |
|
September 9, 2016 |
March 30, 2018 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of California San Diego
San Diego, California, United States - (and 11 more...)
|
11 |
NCT03212404 |
Recruiting |
Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers |
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- (and 7 more...)
|
|
Interventional |
Phase 1 |
- Checkpoint Therapeutics, Inc.
- Novotech (Australia) Pty Limited
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)
- Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)
- (and 8 more...)
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT03212404 |
CK-301-101 |
|
September 20, 2017 |
March 2018 |
December 2020 |
July 11, 2017 |
January 4, 2018 |
|
- Research Site
Wollongong, New South Wales, Australia - Research Site
Box Hill, Victoria, Australia - Research Site
Malvern, Victoria, Australia - Research Site
Christchurch, New Zealand
|
12 |
NCT02936323 |
Recruiting |
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers |
- Neuroendocrine Tumors
- Carcinoma, Small Cell Lung
- Carcinoma, Large Cell Lung
- (and 5 more...)
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment related adverse events
- Maximum concentration of PEN-221 and its metabolites (Cmax)
- Area under the curve (AUC) of PEN-221 and its metabolites
- (and 4 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02936323 |
PEN-221-001 |
|
December 8, 2016 |
June 2019 |
December 2019 |
October 18, 2016 |
June 29, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 5 more...)
|
13 |
NCT03043872 |
Recruiting |
Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) |
- Small Cell Lung Carcinoma Extensive Disease
|
- Drug: Durvalumab
- Drug: Tremelimumab
- Drug: Carboplatin
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival using BICR assessments according to RECIST 1.1
- Objective response rate (ORR) using BICR assessments according to RECIST 1.1
- (and 10 more...)
|
984 |
All |
18 Years to 130 Years (Adult, Senior) |
NCT03043872 |
D419QC00001 2016-001203-23 |
CASPIAN |
March 27, 2017 |
March 29, 2019 |
February 28, 2020 |
February 6, 2017 |
March 23, 2018 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Chandler, Arizona, United States - (and 277 more...)
|
14 |
NCT02937818 |
Recruiting |
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer |
- Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
|
- Drug: Durvalumab and Tremelimumab
- Drug: AZD1775 and carboplatin (CBPT)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Duration of Response (DoR) using Investigator assessments according to RECIST 1.1
- The pharmacokinetics (PK) of MEDI4736 (durvalumab). After the first and steady-state doses: area under the plasma concentration versus time curve (AUC) will be determined
- (and 10 more...)
|
80 |
All |
18 Years to 130 Years (Adult, Senior) |
NCT02937818 |
D419QC00002 2016-001202-42 |
|
November 28, 2016 |
January 22, 2021 |
January 22, 2021 |
October 19, 2016 |
March 29, 2018 |
|
- Research Site
Gauting, Germany - Research Site
Kecskemét, Hungary - Research Site
Miskolc, Hungary - (and 9 more...)
|
15 |
NCT01606293 |
Recruiting |
Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix |
|
- Behavioral: Questionnaires
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Feasibility of Using Social Networking Groups to Survey Patients with Rare Cancers.
|
60 |
Female |
Child, Adult, Senior |
NCT01606293 |
2012-0464 |
|
May 24, 2012 |
May 2019 |
May 2019 |
May 25, 2012 |
January 11, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|